Evolving Treatment Paradigms in the Management of Multiple Sclerosis
 

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum.
If you participated in the live session, you are not eligible for
continuing education credits from this archive.

This activity is valid from July 1, 2021 through August 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Bristol Myers Squibb, Novartis Pharmaceuticals, and Sanofi Genzyme

Description:
Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately 400,000 cases throughout the United States, and every week around 200 people are diagnosed with the disease. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Over the past decade, there have been numerous revisions to MS diagnostic criteria and the development of multiple new and emerging therapies. While the explosion of these emerging therapies have shown the ability to improve outcomes and quality of life in patient's MS, it makes staying current with best practices a challenge that must be overcome through education. New options showing improved efficacy, safety and deliverability have recently been approved, which will change the treatment paradigm, and it is for this reason that medical directors, practicing physicians, nurse case managers and other healthcare professionals must be updated on emerging treatments and strategies in the management of relapsing MS.

Currently treatment is focused on disease-modifying agents, which helps lessen the frequency and severity of relapses, reduce lesions in the brain, and help slow or stop disability. At present time, only one-third to one-half of the 400,000 individuals in the US have received treatment with these disease-modifying agents. While this is not a cure for multiple sclerosis, disease-modifying treatments have greatly improved the quality of life for patients with MS. Many therapeutic and technological advances are helping people manage symptoms, which are highly variable from person to person. Recent years have witnessed remarkable progress in our understanding of the complex mechanisms involved in multiple sclerosis (MS) immunopathophysiology. These new insights have led to late-breaking evidence on treatment options that address unmet needs among patients with relapsing MS disease. It is imperative that medical directors, clinicians, nurses and other healthcare professionals are kept up to date on these emerging treatments for relapsing MS, so they can work together to improve patient compliance and select the appropriate therapy for each patient.

Upon completion of this activity, participants will be able to:

  • Assess the impact of multiple sclerosis (MS) on a patient's quality of life and the burden to the healthcare system

  • Evaluate the latest clinical data on the efficacy, safety, and dosing/administration of current and emerging therapies and their effect on staging and sequencing

  • Differentiate S1P-based disease-modifying therapies (DMTs) for multiple sclerosis (MS) based on clinical evidence for their safety, adherence potential, and efficacy, including clinical data on relapses, MRI lesions, brain volume loss, and disability progression

  • Explore evidence-based approaches for monitoring for insufficient response to therapy, disease worsening, and/or tolerability to support timely and appropriate testing and decision-making related to treatment escalation or switching

  • Implement leading principles, tools, and processes for engaging patients with MS and their caregivers through health plans in personalized shared decision-making on and adherence to MS treatment plans

  • Employ utilization management and benefit design strategies for MS therapies to enhance clinical and economic outcomes for patients with MS

     

Faculty: Benjamin M. Greenberg, MD, MHS, FAAN, FANA, CRND
Director, Perot Foundation Neurosciences Translational Research Center
Professor, Department of Neurology
UT Southwestern

Disclosure:

Dr. Greenberg serves as a consultant for Alexion, EMD Serono, Genentech, Greenwich Bio, Axon Advisors, Novartis, Rubin Anders, and Viela Bio. He serves on the speaker's bureau for AbbVie, Agios, BMS/Celgene, Incyte, Jazz Pharmaceuticals, and Novartis. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Bristol Myers Squibb, Novartis Pharmaceuticals, and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue